RPL17 and breast cancer: High Cdc20 and securin immune expression are associated with extremely poor outcomes in breast cancer patients (Karra et al., 2014), and overexpression of RPL17 affects breast cancer-associated brain metastases (Yuan, Wang & Cheng, 2018).